New anti-HIV drugs show slow but steady progress, with some offering true second-generation advancements over current therapies. Others provide minimal improvements, based on recent studies including the 7th Conference on Retroviruses and Opportunistic Infections.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Discussion:
Key Insights:
Outlook: